Ronit R. Dalmat

Ronit R. Dalmat

Auto-generated profile, based on publicly available information

Ronit R. Dalmat

Department of Global Health, University of Washington

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2021 in Health & Place
Verified
Journal Article
Closed access
RDRonit R. Dalmat
Ronit R. Dalmat
SMStephen J. Mooney
Stephen J. Mooney
PHPhilip Hurvitz
Philip Hurvitz
CZChuan Zhou
Chuan Zhou
AMAnne V. Moudon
Anne V. Moudon
BSBrian E. Saelens
Brian E. Saelens

26 September 2024 in EBioMedicine
Verified
Journal Article
Open access
Paul DrainPaul Drain
Paul Drain
XNXin Niu
Xin Niu
ASAdrienne E. Shapiro
Adrienne E. Shapiro
ZMZanele P. Magcaba
Zanele P. Magcaba
ZNZinhle Ngcobo
Zinhle Ngcobo
BGBen Grant
Ben Grant
Development of a non-sputum test using readily-obtainable biospecimens remains a global priority for tuberculosis (TB) control. We quantified lipoarabinomannan (LAM) concentrations, a pathogen biomarker for Mycobacterium tuberculosis, in urine, plasma and serum for real-world diagnostic accuracy of pulmonary TB among people living with and without HIV. We conducted a prospective diagnostic study among adults with TB symptoms in South Africa. We measured LAM concentrations in time-matched urine, plasma and serum with an electrochemiluminescence immunoassay using two capture antibodies (FIND 28 and S4-20). From the completed cohort, we randomly selected 210 participants (2 cases: 1 control) based on sensitivity estimates, and we compared diagnostic accuracy of LAM measurements against the microbiological reference standard. Urine and blood specimens from 210 of 684 adults enrolled were tested for LAM. Among 138 TB-positive adults (41% female), median urine LAM was 137 pg/mL and 52 pg/mL by FIND 28 and S4-20, respectively. Average LAM concentrations were highest in HIV-positive participants with CD4+ T cells <200 cells/mm3. Urine LAM by S4-20 achieved diagnostic sensitivity of 62% (95% CI: 53%-70%) and specificity of 99% (95% CI: 96%-100%). Plasma and serum LAM by FIND 28 showed similar sensitivity (70%, 95% CI: 62%-78%) and comparable specificities (90%, 95% CI: 82%-97%; 94%, 95% CI: 88%-99%). Diagnostic sensitivity of urine LAM by S4-20 was higher among participants without HIV (41%, 95% CI: 24%-61%) compared to HIV-positive participants with CD4 ≥200 cells/mm3 (20%, 95% CI: 8%-39%). Detection of LAM was achievable in non-sputum specimens for pulmonary TB, but additional analyte concentration or signal amplification may be required to achieve diagnostic accuracy targets. Bill and Melinda Gates Foundation.

24 August 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
Paul DrainPaul Drain
Paul Drain
MBMeagan Bemer
Meagan Bemer
JMJennifer F. Morton
Jennifer F. Morton
RDRonit Dalmat
Ronit Dalmat
HAHussein Abdille
Hussein Abdille
Subhash VermaSubhash Verma
Subhash Verma
Importance: Variants of SARS-CoV-2 have sequence variations in the viral genome that may alter the accuracy of rapid diagnostic tests.Objective: To assess the analytical and clinical accuracy of 2 rapid diagnostic tests for detecting SARS-CoV-2 during 3 phases of variants.Design, Setting, and Participants: This diagnostic study included participants aged 18 years or older who reported onset of COVID-19–like symptoms within the prior 5 days and were tested at multiple COVID-19 testing locations in King County, Washington, from February 17, 2021, to January 11, 2022, during 3 distinct phases of SARS-CoV-2 infection (pre-Delta, Delta, and Omicron).Interventions: Two anterior nasal swab specimens were collected from each participant—1 for onsite testing by the SCoV-2 Ag Detect Rapid Self-Test and 1 for reverse transcriptase–polymerase chain reaction (RT-PCR) testing.Main Outcomes and Measures: The analytical limit of detection of the 2 rapid diagnostic tests (SCoV-2 Ag Detect Rapid Self-Test and BinaxNOW COVID-19 Ag Card) was assessed using Omicron (B.1.1.529/BA.1), Delta (B.1.617.2), and a wild-type (USA-WA1/2020) variant. Diagnostic sensitivity and specificity of clinical testing for the rapid antigen tests were compared with that of RT-PCR testing.Results: A total of 802 participants were enrolled (mean [SD] age, 37.3 [13.3] years; 467 [58.2%] female), 424 (52.9%) of whom had not received COVID-19 vaccination and presented a median of 2 days (IQR, 1-3 days) from symptom onset. Overall, no significant differences were found in the analytical limit of detection or clinical diagnostic accuracy of rapid antigen testing across SARS-CoV-2 variants. The estimated limit of detection for both rapid nucleocapsid antigen tests was at or below a 50% tissue culture infectious dose of 62.5, and the positive percent agreement of the SCoV-2 Ag Detect Rapid Self-Test ranged from 81.2% (95% CI, 69.5%-89.9%) to 90.7% (95% CI, 77.9%-97.4%) across the 3 phases of variants. The diagnostic sensitivity increased for nasal swabs with a lower cycle threshold by RT-PCR, which correlates with a higher viral load.Conclusions and Relevance: In this diagnostic study, analytical and clinical performance data demonstrated accuracy of 2 rapid antigen tests among adults with COVID-19 symptoms across 3 phases of SARS-CoV-2 variants. The findings suggest that home-based rapid antigen testing programs may be an important intervention to reduce global SARS-CoV-2 transmission.

13 September 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
RDRonit R. Dalmat
Ronit R. Dalmat
RZRebecca A. Ziebell
Rebecca A. Ziebell
AKAruna Kamineni
Aruna Kamineni
APAmanda I. Phipps
Amanda I. Phipps
NWNoel S Weiss
Noel S Weiss
JCJessica Chubak
Jessica Chubak
Background: Few empirical data are available to inform older adults’ decisions about whether to screen or continue screening for colorectal cancer based on their prior history of screening, particularly among individuals with a prior negative exam. Methods: Using a retrospective cohort of older adults receiving healthcare at three Kaiser Permanente integrated healthcare systems in Northern California (KPNC), Southern California (KPSC), and Washington (KPWA), we estimated the cumulative risk of colorectal cancer incidence and mortality among older adults who had a negative colonoscopy 10 years earlier, accounting for death from other causes. Results: Screen-eligible adults ages 76 to 85 years who had a negative colonoscopy 10 years earlier were found to be at a low risk of colorectal cancer diagnosis, with a cumulative incidence of 0.39% [95% CI, 0.31%–0.48%) at 2 years that increased to 1.29% (95% CI, 1.02%–1.61%) at 8 years. Cumulative mortality from colorectal cancer was 0.04% (95% CI, 0.02%–0.08%) at 2 years and 0.46% (95% CI, 0.30%–0.70%) at 8 years. Conclusions: These low estimates of cumulative colorectal cancer incidence and mortality occurred in the context of much higher risk of death from other causes. Impact: Knowledge of these results could bear on older adults’ decision to undergo or not undergo further colorectal cancer screening, including choice of modality, should they decide to continue screening. See related commentary by Lieberman, p. 6

14 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
LHLINHUI HAO
LINHUI HAO
THTien-Ying Hsiang
Tien-Ying Hsiang
RDRonit R. Dalmat
Ronit R. Dalmat
RIRenee Ireton
Renee Ireton
JMJennifer F. Morton
Jennifer F. Morton
MGMichael Gale
Michael Gale
New variants of SARS-CoV-2 continue to emerge and evade immunity. We isolated SARS-CoV-2 temporally across the pandemic starting with the first emergence of the virus in the western hemisphere and evaluated the immune escape among variants. A clinic-to-lab viral isolation and characterization pipeline was established to rapidly isolate, sequence, and characterize SARS-CoV-2 variants. A virus neutralization assay was applied to quantitate humoral immunity from infection and/or vaccination. A panel of novel monoclonal antibodies was evaluated for antiviral efficacy. We directly compared all variants, showing that convalescence greater than 5 months post-symptom onset from ancestral virus provides little protection against SARS-CoV-2 variants. Vaccination enhances immunity against viral variants, except for Omicron BA.1, while a three-dose vaccine regimen provides over 50-fold enhanced protection against Omicron BA.1 compared to a two-dose. A novel Mab neutralizes Omicron BA.1 and BA.2 variants better than the clinically approved Mabs, although neither can neutralize Omicron BA.4 or BA.5. Thus, the need remains for continued vaccination-booster efforts, with innovation for vaccine and Mab improvement for broadly neutralizing activity. The usefulness of specific Mab applications links with the window of clinical opportunity when a cognate viral variant is present in the infected population.

25 November 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
JCJessica Chubak
Jessica Chubak
LILaura E. Ichikawa
Laura E. Ichikawa
SMSophie A. Merchant
Sophie A. Merchant
RDRonit R. Dalmat
Ronit R. Dalmat
RZRebecca A. Ziebell
Rebecca A. Ziebell
TLTheodore R. Levin
Theodore R. Levin
Background: Screening colonoscopy harm data are limited for adults ages 76 to 85 years. Methods: We conducted a retrospective cohort study of screening colonoscopies versus fecal immunochemical tests (FIT) and general population matched comparators ages 76 to 85 years within three integrated healthcare systems (2010–2019). The primary outcome was death or overnight hospitalization within 30 days. A secondary outcome also included nine harm diagnoses. Adjusted risk estimates and risk differences (RD) were obtained using Poisson regression. Narrow analyses excluded outcomes after the next lower endoscopy or colorectal procedure, whereas broad analyses included them. Results: Patients undergoing screening colonoscopy (N = 4,435) had a higher 10-day cumulative incidence of gastrointestinal bleeding {0.18% [95% confidence interval (CI), 0.09%–0.35%]} and perforation [0.09% (95% CI, 0.03%–0.23%)] than those with FIT (N = 17,740) and the general population (N = 44,350) in the narrow analysis. Screening colonoscopy patients had a 1.04% (95% CI, 0.74%–1.34%) risk of death or hospitalization within 30 days in the narrow analysis, similar to those with FIT [RD = 0% (95% CI, −0.36% to 0.35%)] and the general population [RD = −0.07% (95% CI, −0.39% to 0.25%)]. In the broad analysis, risk following colonoscopy was 2.30% (95% CI, 1.85%–2.75%) with RD = 1.13% (95% CI, 0.67%–1.60%) versus general population [ages 76–80 years: RD = 0.93% (95% CI, 0.45%–1.41%) and ages 81–85 years: RD = 2.14% (95% CI, 0.74%–3.54%)]. Secondary outcomes followed a similar pattern by age. Conclusions: At ages 76 to 85 years, screening colonoscopies including downstream procedures are associated with an increased short-term risk of death or hospitalization. Impact: Harm data can be combined with benefit data to guide screening colonoscopy decisions among older adults.